Literature DB >> 10728027

Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

A Girolami, P Simioni, L Scarano, B Girolami, P Zerbinati.   

Abstract

A family with a combined deficiency of factor XII and factor V Leiden is presented. The proposita is a 72-year-old who showed a mild to moderate thrombotic tendency characterized by two episodes of deep venous thrombosis and superficial phlebitis between the age of 50 and 71. She was shown to be carrier of homozygous factor XII deficiency and heterozygous FV Leiden mutation. A sister of the proposita showed the same pattern but remained asymptomatic. Other family members showed either isolated heterozygous factor XII deficiency or combined heterozygous factor XII deficiency and heterozygous FV Leiden mutation but were all asymptomatic. These data lend support to those who maintain that FV Leiden is a mild genetic determinant for thrombosis. The role of FXII deficiency as an additional risk factor remains questionable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728027     DOI: 10.1023/a:1018774813568

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  28 in total

1.  Emphasis on congenital conditions predisposing to thrombosis should not make us disregard the importance of acquired factors.

Authors:  A Girolami; L Scarano; B Girolami; A Marchiori
Journal:  Blood Coagul Fibrinolysis       Date:  1998-10       Impact factor: 1.276

2.  Thrombophilia with a combination of antithrombin III and factor XII deficiency.

Authors:  N Maurin; H Schunkert; H G Sieberth
Journal:  Thromb Haemost       Date:  1988-08-30       Impact factor: 5.249

3.  Letter: Thromboembolic accidents in patients with congenital deficiency of factor XII.

Authors:  J Aznar; A Fernandez Pavon
Journal:  Thromb Diath Haemorrh       Date:  1974-06-30

4.  Cholecystectomy in a patient with Hageman trait.

Authors:  A Girolami; A Maffei; A Brunetti; M Lazzarin
Journal:  Thromb Diath Haemorrh       Date:  1970-06-30

5.  Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraception.

Authors:  A Girolami; P Simioni; B Girolami; P Radossi
Journal:  Blood Coagul Fibrinolysis       Date:  1996-09       Impact factor: 1.276

6.  Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.

Authors:  E M Faioni; F Franchi; D Asti; E Sacchi; F Bernardi; P M Mannucci
Journal:  Thromb Haemost       Date:  1993-12-20       Impact factor: 5.249

7.  "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.

Authors:  P Simioni; A Scudeller; P Radossi; S Gavasso; B Girolami; D Tormene; A Girolami
Journal:  Thromb Haemost       Date:  1996-03       Impact factor: 5.249

8.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

9.  Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.

Authors:  B P Koeleman; P H Reitsma; C F Allaart; R M Bertina
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

10.  Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis.

Authors:  A A Arbini; P M Mannucci; K A Bauer
Journal:  Thromb Haemost       Date:  1995-11       Impact factor: 5.249

View more
  4 in total

Review 1.  Pregnancies and oral contraceptive therapy in severe (homozygons) FXII deficiency: a study in 12 patients and review of the literature.

Authors:  A Girolami; N Zocca; B Girolami; A M Lombardi; F Fabris
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

2.  Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

Authors:  A Girolami; N Candeo; G Berti De Marinis; E Bonamigo; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

3.  Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.

Authors:  Antonio Girolami; Silvia Ferrari; Elisabetta Cosi; Bruno Girolami; Maria Luigia Randi
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 4.  The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

Authors:  A Girolami; M L Randi; S Gavasso; A M Lombardi; F Spiezia
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.